All News

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

Lilly opens early access to retatrutide for some patients before FDA approval, following scrutiny over a single earlier compassionate-use case.

The former deputy surgeon general takes over an agency that has lacked permanent leadership since Susan Monarez, PhD, was ousted.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

The accreditation body targets sourcing, testing, and marketing practices, as the FDA advisory panel recommends expanding access to compounded peptides.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Summer heat may accelerate microplastic exposure, raising concerns about health effects and climate impacts.

GPBCH's podcast series helps employers navigate GLP-1 strategy and oncology care access, pairing data-driven insights with patient literacy tools.

At an AJMC roundtable, Boston clinicians detailed fragmented obesity care access, prior authorization burdens, and looming GLP-1 coverage shifts.

Novartis says it can deliver doses to treatment sites with 5 days of order.

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.

The researchers of this study warn a mismatch could deepen care gaps for LGBTQ+ patients in restrictive states.

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.

Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.

The new MonumenTAL-6 combination data appear to exceed MajesTEC-9 numbers.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

People with HIV born after 1980 had an 81% lower risk of hepatitis B coinfection than earlier cohorts, highlighting the lasting impact of childhood vaccination.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

In the DELTA TEEN trial, 64% of adolescents with moderate to severe chronic hand eczema achieved clear or almost clear skin with delgocitinib cream versus 29% on vehicle, with mostly mild adverse events and no safety signals.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Alvin Thomas, PhD, discusses social media, discrimination, and mental health challenges affecting Black and Latino youth.